Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farlow, M. R.
Right arrow Articles by Evans, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farlow, M. R.
Right arrow Articles by Evans, R. M.
NEUROLOGY 1998;51:S36-S44
© 1998 American Academy of Neurology

Pharmacologic treatment of cognition in Alzheimer's dementia

Martin R. Farlow, MD and Rebecca M. Evans, MD

From the Department of Neurology, Indiana University, Indianapolis, IN.

Address correspondence and reprint requests to Dr. Martin Farlow, Department of Neurology, Indiana University, Clinical Building 583, 541 Clinical Drive, Indiana University Medical Center, Indianapolis, IN 46202-5111.

Abstract.

Much of the treatment research and development for Alzheimer's disease(AD) in recent years has been based on the cholinergic hypothesis. Cholinesterase inhibition has been shown to improve the symptoms of mild to moderate AD. Two cholinesterase inhibitors (CIs) are now available and two more may be available shortly. Free radical inhibitors, estrogen, and anti-inflammatory drugs may also delay the onset and slow progression of AD. Combination therapies employing CIs and these other drugs may prove successful in the future.




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
L. A. Volpicelli-Daley, A. Hrabovska, E. G. Duysen, S. M. Ferguson, R. D. Blakely, O. Lockridge, and A. I. Levey
Altered Striatal Function and Muscarinic Cholinergic Receptors in Acetylcholinesterase Knockout Mice
Mol. Pharmacol., December 1, 2003; 64(6): 1309 - 1316.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
W. S. Moore
Resolved: NASCET and ACAS Need Not Be Repeated: The Affirmative Position
Arch Neurol, May 1, 2003; 60(5): 775 - 778.
[Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
K Rockwood, J Mintzer, L Truyen, T Wessel, and D Wilkinson
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
J. Neurol. Neurosurg. Psychiatry, November 1, 2001; 71(5): 589 - 595.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. A. Raskind, E. R. Peskind, T. Wessel, and W. Yuan
Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
Neurology, June 27, 2000; 54(12): 2261 - 2268.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. N. Tariot, P. R. Solomon, J. C. Morris, P. Kershaw, S. Lilienfeld, and C. Ding
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Neurology, June 27, 2000; 54(12): 2269 - 2276.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
R. Luckmann
Metrifonate was effective in mild to moderate Alzheimer's disease
Evid. Based Ment. Health, November 1, 1998; 1(4): 116 - 116.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.